Q-omics provides the consensus-scored SYNCRIP profile across patient tissues and cancer cell-line models. SYNCRIP expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SYNCRIP is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, SYNCRIP protein abundance shows 36,316 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, THCA, and PDAC as cancer lineages where SYNCRIP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYNCRIP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYNCRIP survival associations across molecular data types. SYNCRIP RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYNCRIP RNA expression–survival associations across cancer types. High SYNCRIP expression shows unfavorable associations in MESO, LIHC and ACC, but favorable associations in UCS, OV and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SYNCRIP RNA expression.
This table summarizes SYNCRIP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 11. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SYNCRIP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYNCRIP shows lower tumor expression in THCA and KICH and higher tumor expression in STAD, HNSC, COAD and LIHC. The THCA box plot shows higher SYNCRIP RNA expression in normal versus tumor tissue (log2 FC = −0.900, t-test p < 0.001).
This table shows molecular features associated with SYNCRIP in patient tissues and cancer cell lines. In patient samples, SYNCRIP shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SYNCRIP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
